Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn's Disease
Shots:
- Eli Lilly has reported 2yrs. data from VIVID-2 (OLE) study (incl. 1yr. of VIVID-1) of Omvoh for mod. to sev. Crohn's disease; regulatory review is underway in China, Canada, Japan & other regions
- In VIVID-1, 92.9% pts sustained clinical remission (CDAI) and 78.6% retained endoscopic remission (SES-CD ≤4 & ≥2-point decrease, with no subscore >1/variable) at 2yrs., whereas 87.6% maintained endoscopic response (intestinal healing, ≥50% SES-CD reduction) in VIVID-2. Also, 60.8% & 35.4% of non-responders gained clinical & endoscopic remission, respectively in 2yrs. Data to be presented at the CCC 2025
- Omvoh is also being assessed in pediatric & adults for Crohn's disease & UC, plus in a P-IV RWE study in UC pts
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Receives the US FDA’s Approval for Omvoh (Mirikizumab-mrkz) to Treat Crohn's Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
